Barron’s 2024 Healthcare Roundtable panelists make the case for 21 healthcare companies of all stripes, including Humana, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Cantor initiated Amgen (AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech company’s ...

Federman & Sherwood investigates Amgen, Inc. for data breach. Amgen became aware of a cybersecurity incident that involved one of their service providers, Sirva Relocation, LLC and its parent company ...

Led by strong returns for shares of Amgen and Chevron, the Dow Jones Industrial Average is climbing Friday afternoon.

Amgen (AMGN) ended the recent trading session at $322.67, demonstrating a +1.12% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.13%.

On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Rheumatologists and lab specialists generally support consumers' ability to access tests without a doctor's order, but they remain aware of the possible harms that can come with practice.

Hippocratic AI is developing a generative AI model that aims to help providers complete non-diagnostic and patient-facing tasks ...

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. Vandana ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...